CD274 and neoplasm: Despite the potential loss of the PD-L1 immune-evasion mechanism in tumor cells, there is a possibility that the efficacy of anti-PD-L1/anti-PD-1 therapy might be maintained via the inhibition of T-cell exhaustion in other locations, such as lymph nodes [72].